Background: High-dose chemotherapy and autologous stem cell transplantation have become a standard curative treatment in various hematologic malignancies. Many factors can affect the success of mobilization and hematopoietic stem cell harvesting.
Aim: The aim of this study was to analyze factors that lead to mobilization failure.
Material and Methods: We conducted a retrospective study on 19 patients with failure of stem cell harvesting. All patients were administered high doses of GCS-F (filgrastim, 15 μg/kg/day) and 0.24 mg/kg of plerixafor on day +5 or +10 of harvesting.
Results: The median age of the study population was 51 years (range 35–67) and 52.6% (n = 10) were males. The study group included 4 (21%) subjects with multiple myeloma, 6 (31.5%) with Hodgkin lymphoma, 8 cases (42.1%) with non-Hodgkin lymphoma and 1 patient with chronic lymphocytic leukemia. Each patient received 2.78 (range 1–5) lines of chemotherapy, administered in 11.57 (range 2 to over 20) cycles of treatment.
Conclusion: In hematologic malignancies it is very important to collect stem cells in time, in order to reduce mobilization failure. As we have shown in our studied cases, multiple lines of polychemotherapy with or without radiotherapy lead to mobilization failure.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Korbling M Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cell matter? Blood. 2001;98:2900-2908.
2. To LB Haylock DN Simmons PJ Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997; 89:2233-2258.
3. Jillella AP Ustun C. What is the optimum number of CD34 peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 2004;13:598-606.
4. Vose JM Ho AD Coiffier B et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma. 2009;50:1412-1421.
5. Sancho JM Morgades M Grifols JR et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+ cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy. 2012;14:823-829.
6. To LB Levesque JP Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118:4530-4540.
7. Verfaillie CM. Hematopoietic stem cells for transplantation. Nature Immunology. 2002;3:314-317.
8. Pozotrigo M Adel N Landau L et al. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the area of novel therapies: experience at Memorial Sloan Kattering Cancer Center. Bone Marrow Transplantation. 2013;48:1033-1039.
9. Worel N Rosskopf K Neumeister P et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion. 2011;51:968-975.
10. Nur Ozkurt Z Yegin AZ Suyan E et al. Factors Affecting Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation. Journal of Clinical Apheresis. 2010;25:280-286.